Novavax reported $1.65B in Current Liabilities for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Adamas Pharmaceuticals ADMS:US 21.82M 7.35M
Adma Biologics ADMA:US $ 18.19M 3.02M
Agenus AGEN:US $ 168.75M 30.38M
AstraZeneca AZN:LN 22222M 709M
Astrazeneca AZN:US $ 22222M 709M
BioSpecifics Technologies BSTC:US 1.54M 2.3M
Dynavax Technologies DVAX:US $ 204.64M 95.22M
Genocea Biosciences GNCA:US $ 14.83M 3.41M
Geron GERN:US $ 37.01M 8.46M
GlaxoSmithKline GSK:LN 21387M 1112M
Kindred Biosciences KIN:US $ 11.26M 4.71M
Mannkind MNKD:US $ 60.43M 12.69M
Minerva Neurosciences NERV:US $ 4.44M 1.08M
Moderna Inc MRNA:US 8.84B 399M
Novartis NVS:US $ 29633M 527M
Novavax NVAX:US $ 1651.52M 442.96M
Pain Therapeutics PTIE:US $ 4.64M 1.99M
Peregrine Pharmaceuticals PPHM:US $ 63.25M 7.69M
Sarepta Therapeutics SRPT:US $ 425.02M 60.29M